In October 2004, Biosyn was acquired by Cellegy Pharmaceuticals (Nasdaq: CLGY), a specialty biopharmaceutical company also active in the SBIR program. Biosyn is a specialty pharmaceutical company focused on the development and commercialization of novel drugs in the areas of infectious disease and reproductive health. Biosyn is an anti-infective drug company focused on the development of novel, targeted-delivery drugs for the treatment and prevention of infectious disease. novel contraceptive gel for the prevention of HIV in women
